MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
(NASDAQ: INKT) Delayed: 12.02 -0.32 (2.59%)
Previous Close $12.34    52 Week High $ 
Open $12.55    52 Week Low $ 
Day High $12.68    P/E N/A 
Day Low $11.80    EPS $ 
Volume 28,191